T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors
T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) ...
Yahoo Finance9d
T-knife Therapeutics to Participate in Two Investor Conferences in March
Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today ...
Medscape11d
Promise for CAR T-Cell Therapies in Solid Tumors?
CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...
Morningstar3d
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T ...
Mena FN10d
T-Cell Receptor Therapy Market Poised For Remarkable Growth By 2032 Delveinsight
Unlike CAR-T cell therapy, which recognizes surface antigens, TCR therapy is engineered to identify intracellular antigens presented by major histocompatibility complex (MHC) molecules ...
labiotech3d
T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies ...
Pharmabiz2d
Medigene’s JOVI technology receives US patent
Medigene AG, an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced that the company has been issued a ...